Novo Nordisk’s Wegovy and copyright, each run by semaglutide, have revolutionized being overweight procedure by way of unparalleled weight loss results.In October 2024, Novo Nordisk revealed a examine on scientific journal Nature a few novel glucose-sensitive insulin NNC2215 that could decrease the potential risk of hypoglycemia in animal styles.